People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

according to a Reuters report citing wide-scale analysis of pharmacy claims in the country. The first time I was on Mounjaro, I mistakenly dropped the drug from a high dose to nothing ...

That said, I think, we're dealing with a kind of a business here that is pretty unprecedented in our sector in terms of size, and scale ... things went well too. Mounjaro had a very strong ...

The company argued that following a $23 billion manufacturing scale-up campaign, all doses of Mounjaro and Zepbound ... the FDA listed the final remaining dose of Novo’s semaglutide-based ...

There are precedents for a hybrid NHS-private model of healthcare. Ten years ago, a new drug treatment arrived that could ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound ... will further strengthen our process development and scale up our manufacturing capabilities to speed delivery ...

Lilly is making Mounjaro available to the NHS at a confidential discount to the drug's list price of between £92 and £122 – depending on dose – for ... on a national scale, benefitting ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

On Christmas Day, when Tesla CEO Elon Musk posed as a slim Santa Claus on X, he gave an unmatched public profile to the anti-obesity drugs Mounjaro and Ozempic with one comment. “Like Cocaine ...